Insider Buying: Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) CEO Buys $24,000.00 in Stock

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) CEO Brian M. Culley bought 40,000 shares of Lineage Cell Therapeutics stock in a transaction dated Thursday, November 21st. The stock was purchased at an average cost of $0.60 per share, with a total value of $24,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 194,842 shares in the company, valued at approximately $116,905.20. The trade was a 25.83 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

Lineage Cell Therapeutics Stock Down 16.0 %

LCTX opened at $0.50 on Monday. The company has a market cap of $95.16 million, a price-to-earnings ratio of -4.20 and a beta of 1.28. Lineage Cell Therapeutics, Inc. has a 52 week low of $0.50 and a 52 week high of $1.61.

Analyst Upgrades and Downgrades

Separately, Craig Hallum began coverage on Lineage Cell Therapeutics in a report on Tuesday, August 20th. They issued a “buy” rating and a $4.00 target price for the company.

Institutional Trading of Lineage Cell Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in LCTX. SG Americas Securities LLC purchased a new position in shares of Lineage Cell Therapeutics during the 3rd quarter worth approximately $46,000. XTX Topco Ltd purchased a new position in shares of Lineage Cell Therapeutics during the 2nd quarter worth approximately $61,000. GSA Capital Partners LLP purchased a new position in shares of Lineage Cell Therapeutics during the 3rd quarter worth approximately $84,000. Rhumbline Advisers raised its stake in shares of Lineage Cell Therapeutics by 15.1% during the 2nd quarter. Rhumbline Advisers now owns 132,491 shares of the company’s stock worth $132,000 after buying an additional 17,411 shares in the last quarter. Finally, Barclays PLC raised its stake in shares of Lineage Cell Therapeutics by 311.3% during the 3rd quarter. Barclays PLC now owns 211,300 shares of the company’s stock worth $192,000 after buying an additional 159,924 shares in the last quarter. 62.47% of the stock is owned by hedge funds and other institutional investors.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.